Bayer's PET agent meets endpoints in phase III cardiac amyloidosis study

Bayer's investigational PET imaging agent demonstrated strong diagnostic performance in phase III trials for cardiac amyloidosis, achieving 94% sensitivity and 86% specificity. The positive results advance development of this medical device for improved cardiac disease detection.